Open-Label, Dose-Escalation, Pilot Study of PRT-201 Administered Following Angioplasty in Patients With Peripheral Artery Disease in the Lower Extremity
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2016
Price : $35 *
At a glance
- Drugs Vonapanitase (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions
- Sponsors Proteon Therapeutics
- 25 Oct 2016 According to Proteon Therapeutics media release, overview of this trial will be presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation.
- 12 Oct 2015 Results of this trial were presented at the 27th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, according to a Proteon Therapeutics media release.
- 13 Aug 2015 Topline results are published in a Proteon therapeutics Media Release. The company is still doing a complete analysis and the full results will be announced at a major medical meeting in the future.